Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.6638 -0.0072 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
From Vistagen
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Revolutionary Biotech Stocks Poised for 10X Surge ↗
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. 
Via InvestorPlace
News headline image
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave ↗
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. 
Via InvestorPlace
News headline image
Recap: Vistagen Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
VistaGen Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
VistaGen Therapeutics Earnings Preview ↗
 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
Via Investor Brand Network
News headline image
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
3 Penny Stocks to Buy for the Next Bull Run: February 2024 ↗
As the market pivots in 2024, dive into the dynamic world of penny stocks, revealing the top choices for February's exhilarating bull run. 
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call
Via Investor Brand Network
News headline image
Earnings Scheduled For February 13, 2024 ↗
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
News headline image
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
From Vistagen
Via Business Wire
News headline image
3 Penny Stocks to Turn $999 Into $1 Million: January 2024 ↗
With our strengthening economy, you need to invest in penny stocks that will deliver high future returns, these three are your best bets. 
Via InvestorPlace
Topics Economy
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
Via Investor Brand Network
Topics Intellectual Property
News headline image
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
News headline image
Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment ↗
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety... 
Via Benzinga
News headline image
Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst ↗
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder... 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2024 Financial Report, Corporate Update
Via Investor Brand Network
News headline image
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
From Vistagen
Via Business Wire
News headline image
Earnings Scheduled For November 9, 2023 ↗
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
News headline image
Vistagen to Present at Stifel 2023 Healthcare Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Plans to Present Positive Study Results at Conferences in November
Via Investor Brand Network
News headline image
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q2 Results, Corporate Update Conference Call
Via Investor Brand Network
News headline image
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
From Vistagen
Via Business Wire
News headline image
Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Inaugural Biotech CNS/Neuro Summit
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.